Contract Pharma1d
Verdiva Bio Launches as Clinical-Stage Cardiometabolic Company
With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...
Viridian Therapeutics: Strategic Positioning and First-Mover Advantage in the TED Market
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...
Viridian Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
Stifel Nicolaus analyst Alex Thompson CFA has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...